COMPANY PROFILE

Philogen

Explore full profile

Develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders

Sovicille, ItalyFounded 1996Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Revenue $100–500M Latest reported FY

Headcount 100–500 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Philogen

Philogen is a Swiss-Italian biotechnology company founded in 1996, specializing in the development of innovative biopharmaceuticals for treating angiogenesis-related disorders, which involve the formation of new blood vessels. The company operates in the biopharmaceutical market, focusing on the discovery, GMP production, and clinical development of targeted therapeutics, particularly antibody-based treatments. Philogen serves large pharmaceutical companies through numerous collaborative agreements and partnerships. Its business model revolves around the development and commercialization of proprietary therapeutics, generating revenue through licensing deals, milestone payments, and royalties. The company leverages its expertise in antibody engineering and targeted drug delivery to maintain a leading position in its field. Keywords: biopharmaceuticals, angiogenesis, antibody-based therapeutics, biotechnology, clinical development, GMP production, targeted therapeutics, pharmaceutical partnerships, drug discovery, innovative treatments.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 1996
Headquarters: Sovicille, Italy
Employees: 183
Open positions: 11
Dealroom signal: 83.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, Longevity, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPOOther financing	Mar 2021	$69M	$690M	Undisclosed	↗
LATE VCOther financing	May 2019	$68M	$273M	The Equity Club · Mediobanca	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Philogen website traffic

Latest recorded traffic for Philogen is 5.3K monthly website visits, down 8.6% over the last three months. Philogen's team grew 8.3% over the past year.

Latest monthly visits5.3K 3-month web change-8.6% 1-year team growth+8.3%

Monthly website visitsNov 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Human Resources InternSiena, Tuscany, Italy · Human Resources · Jul 19, 2026 Senior Full-Stack Software EngineerMilan, Lombardy, Italy · Full-Stack Development · Jul 19, 2026 Data & AI InternMilan, Lombardy, Italy · Data Science & Engineering · Jul 16, 2026 Life Sciences Solutions EngineerMilan, Lombardy, Italy · Other · Jul 16, 2026 Impiegato/a Categorie ProtetteSiena, Tuscany, Italy · Other · Jul 5, 2026 Statistical Programmer InternSiena, Tuscany, Italy · Data Science & Engineering · Jul 2, 2026 Process & Computer System Validation Specialist (GCP)Siena, Tuscany, Italy · Backend Development · Feb 24, 2026

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational	1	$7.8M	$17M
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational
STSenolytic TherapeuticsA discovery-stage biotech developing novel medicines that target senescent cells	Barcelona, Spain	Closed
SOSentinel OncologyTargeted oncology candidate drugs for brain tumours	Cambridge, United Kingdom	Operational
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational
LHLegacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology	Epalinges, Switzerland	Operational
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational